에 대한 최신 뉴스 Kaspi.kz (NASDAQ:KSPI) 주식

Kaspi.kz

Kaspi.kz JSC is the payment, marketplace, and Fintech ecosystem in Kazakhstan. The firm provides interconnected technologically seamless products and services that help people to pay, shop, and manage their finances. Its operating segment includes the Payments Platform that connects its customers, which consist of both consumers and merchants, to facilitate cashless, digital transactions, the Marketplace Platform that connects merchants and consumers enabling merchants to increase their sales and consumers to buy a broad selection of products and services offered by a variety of merchants, and Fintech Platform that enables customers to manage their personal finances online and access consumer finance and deposit products through the Kaspi.kz Super App.

Large Cap

News

Movers

Trading Ideas

ASND

BMRN

BNTX

CHWY

KSPI

MUSA

RIVN

SMMT

이들 10개 대형주는 지난주 최악의 성과를 거두었다. 그것들이 당신의 포트폴리오에 있나요? 1. 서밋 테라퓨틱스(NASDAQ:SMMT)의 주식이 23.61% 하락했다. 이 회사는 새롭고 잠재적인 최초의 연구용 이중특이성 항체인 아이보네스시맙(ivonescimab)에 대한 데이터가 2024년 ESMO 연례 회의에서 발표되었다고 발표했다.

노보 노디스크, 츄이 및 페덱스는 지난주 최악의 성과를 보인 10개 대형주 중 일부 (9월 15일-9월 21일)

Joint Stock Company Kaspi.kz - American Depository Shares

Kaspi.kz JSC

Wedbush analyst Nick Setyan reiterates Dine Brands Global (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DIN#NYSE">DIN</a>) with a Outperform and maintains $47 price target.

Price Target

Reiteration

Analyst Ratings

Wedbush Reiterates Outperform on Dine Brands Global, Maintains $47 Price Target

Piper Sandler analyst Edward Tenthoff maintains Omega Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OMGA#NASDAQ">OMGA</a>) with a Overweight and lowers the price target from $9 to $4.

OMGA

Piper Sandler Maintains Overweight on Omega Therapeutics, Lowers Price Target to $4

WIIM

BABA

Alibaba Group Holding shares are trading higher after the company reported better-than-expected Q2 sales results.

Piper Sandler analyst Kashy Harrison upgrades Bloom Energy (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BE#NYSE">BE</a>) from Neutral to Overweight and raises the price target from $10 to $20.

Upgrades

Piper Sandler Upgrades Bloom Energy to Overweight, Raises Price Target to $20

AMAT

Applied Materials shares are trading lower following Q1 financial results. Also, multiple firms lowered their respective price targets on the stock.

HC Wainwright &amp; Co. analyst Swayampakula Ramakanth reiterates Precigen (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PGEN#NASDAQ">PGEN</a>) with a Buy and maintains $4 price target.

PGEN

HC Wainwright & Co. Reiterates Buy on Precigen, Maintains $4 Price Target

The World Health Organization (WHO) on Friday described vaccines as &#8220;absolutely critical&#8221; to global health, adding that many people alive today would not have survived childhood without them. This comes at after Donald Trump&#8216;s announcement of Robert F. Kennedy Jr. as Health Secretary.
What Happened: As per <a href="https://pro.benzinga.com">Benzinga Pro</a> on Friday, health stocks declined further during pre-market hours. Pfizer Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PFE#NYSE">PFE</a>) saw a 0.58% drop after closing 2.62% lower at $26.02. Moderna Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRNA#NASDAQ">MRNA</a>) was down by 1.56% while AstraZeneca plc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AZN#NASDAQ">AZN</a>) fell by 1.41%, and Novavax Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVAX#NASDAQ">NVAX</a>) decreased by 1.39%, having already dropped 7.02% to $7.22.
While the spokesperson for WHO did not comment on Kennedy Jr&#8217;s appointment directly, she mentioned that the U.S. is an important United Nations member and hoped the &#8220;fantastic work&#8221;&nbsp; would continue, <a href="https://www.bbc.com/news/live/c0lp93494g9t?post=asset%3Afdf8e84f-8eb1-45b0-9e05-4ad5adad709b#post">as</a> per BBC news.
Trump&#8217;s decision to appoint Kennedy, known for his vaccine skepticism and conspiracy theories has sparked significant attention. The move aligns with Kennedy&#8217;s recent endorsement of Trump after ending his presidential bid.
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">Thank you <a href="https://twitter.com/realDonaldTrump?ref_src=twsrc%5Etfw">@realDonaldTrump</a> for your leadership and courage. I&#39;m committed to advancing your vision to Make America Healthy Again. We have a generational opportunity to bring together the greatest minds in science, medicine, industry, and government to put an end to the chronic…
&mdash; Robert F. Kennedy Jr (@RobertKennedyJr) <a href="https://twitter.com/RobertKennedyJr/status/1857198805919138235?ref_src=twsrc%5Etfw">November 14, 2024</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
See Also: <a href="https://www.benzinga.com/general/biotech/24/11/41947492/syros-pharmaceuticals-stock-sinks-as-pivotal-blood-cancer-trial-flunks-triggers-loan-default?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">Syros Pharmaceuticals Stock Sinks As Pivotal Blood Cancer Trial Flunks, Triggers Loan Default</a>
Why It Matters: The appointment of Kennedy, a prominent critic of vaccines, as Health Secretary could signal a shift in national health policies. Trump&#8217;s choice has <a href="https://www.benzinga.com/government/regulations/24/11/41993115/trump-taps-rfk-jr-for-health-secretary-role-sends-5-vaccine-stocks-lower">elicited mixed reactions</a>, particularly among public health experts. Kennedy&#8217;s stance on vaccines may influence future health regulations and policies.
Kennedy&#8217;s views on vaccines <a href="https://www.benzinga.com/government/regulations/24/11/41993115/trump-taps-rfk-jr-for-health-secretary-role-sends-5-vaccine-stocks-lower">and health agencies diverge sharply</a> from mainstream medical consensus. He has consistently propagated debunked claims, including the false assertion that vaccines cause autism—a theory discredited by extensive scientific research. His nomination for HHS secretary comes amid declining vaccination rates, which have contributed to public health challenges such as 13 measles outbreaks reported in the U.S. this year.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/general/biotech/24/11/41915173/abbvies-schizophrenia-failure-disappoints-but-analysts-show-confidence-in-immunology-portfolio?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">AbbVie&#8217;s Schizophrenia Failure Disappoints But Analysts Show Confidence In Immunology Portfolio</a></li>
</ul>
Image via Shutterstock

Biotech

Health Care

Pre-Market Outlook

Markets

General

MRNA

NVAX

WHO Calls Vaccines 'Absolutely Critical' As Trump's Appointment Of RFK Jr Pulls Pzifer, Moderna Stocks Downhill

Morgan Stanley analyst Simeon Gutman maintains Sally Beauty Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SBH#NYSE">SBH</a>) with a Underweight and raises the price target from $8 to $12.

Morgan Stanley Maintains Underweight on Sally Beauty Holdings, Raises Price Target to $12

ValueAct Holdings, L.P. reported holdings worth $3.9 billion in the September quarter after it disclosed major changes in its 13F filing for the third quarter of current fiscal. 
What Happened: One of the major changes in its holdings during Q3 was the addition of 211,500 shares of Meta Platforms Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/META#NASDAQ">META</a>) for $121.07 million, representing 3.08% of its total portfolio.
ValueAct Holdings is a hedge fund popularly known for its activist strategies, run by chief executive officer, Mason Morfit. An activist hedge fund usually follows an event-driven strategy and acquires sufficient equity to influence a company's policies, to increase company value. ValueAct has a long history of investing in technology companies and is generally considered to be more constructivist and collaborative than other activist funds.
ValueAct did not immediately respond to <a href="http://pro.benzinga.com">Benzinga&#8217;s</a> request for comment.
In 2022, Brad Gerstner&#8216;s Altimeter Capital targeted Meta, urging the company to reduce its workforce. Gerstner articulated his concerns in <a href="https://www.benzinga.com/news/22/10/29380959/meta-investor-proposes-curb-on-employees-strength-metaverse-spending">a letter titled &#8220;Time to Get Fit.</a>
ValueAct fund's specific intentions remain unclear, but CEO Morfit is reportedly supportive of Meta CEO Mark Zuckerberg&#8217;s strategic focus on advancing artificial intelligence initiatives, <a href="https://www.cnbc.com/2024/11/12/activist-valueact-has-1-billion-stake-in-meta-sources-say.html">according</a> to CNBC.
Why It Matters: According to its Q3 <a href="https://13f.info/13f/000141881224000021/compare/000141881224000017">13F filing</a>, ValueAct has acquired a passive stake in the parent company of Facebook, Instagram and WhatsApp, namely, Meta. It is one of the largest companies to be targeted by an activist investor, with a market cap of nearly $1.5 trillion. The hedge fund also increased its investment in <a href="https://www.benzinga.com/m-a/24/01/36471982/disney-partners-with-valueact-capital-for-strategic-counsel-in-anticipation-of-2024-shareholder-meet">The Walt Disney Co</a> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DIS#NYSE">DIS</a>) by adding 1.33 million shares taking its total value to $718.04 million in ValueAct&#8217;s portfolio.
Also Read: <a href="https://www.benzinga.com/economics/macro-economic-events/24/11/42001972/chinese-retail-sales-pickup-in-october-heres-whats-happening-with-alibaba-jd-and-pinduoduo-shares">Chinese Retail Sales Pickup In October: Here&#8217;s What&#8217;s Happening With Alibaba, JD And Pinduoduo Shares</a>
Other Key Changes To The Portfolio
Apart from adding Meta, ValueAct has made some major changes to its portfolio which consists of ten holdings. The fund has increased its stake in the American video game developer Roblox Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RBLX#NYSE">RBLX</a>) by adding 7.83 million shares in Q3. It now represents 8.81% of ValueAct&#8217;s portfolio, having a total value of $448.62 million.
Live Nation Entertainment Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LYV#NYSE">LYV</a>), Visa Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/V#NYSE">V</a>) and Liberty Media Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LLYVK#NASDAQ">LLYVK</a>) are other new holdings that ValueAct has added to its portfolio.
The hedge fund also reduced 806.96 thousand shares in Expedia Group Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EXPE#NASDAQ">EXPE</a>) and completely exited Spotify Technology SA (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPOT#NYSE">SPOT</a>), Finserv Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FI#NYSE">FI</a>), KKR &amp; Co Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KKR#NYSE">KKR</a>), New York Times Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NYT#NYSE">NYT</a>) and Flutter Entertainment PLC (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FLUT#NYSE">FLUT</a>).
Read next: &nbsp;<a href="https://www.benzinga.com/general/market-summary/24/11/41968003/gold-drops-to-a-two-month-low-as-investors-turn-to-bitcoin-after-trumps-victory-but-this-economist-remains-confident-that-gold-will-surge" target="_blank" rel="noreferrer noopener">Gold Drops To A Two-Month Low As Investors Turn To Bitcoin After Trump's Victory, But This Economist Remains Confident That ‘Gold Will Surge'</a>
Image via Wikimedia Commons

Equities

Tech

EXPE

FLUT

LLYVK

RBLX

SPOT

Activist Hedge Fund ValueAct Boosts Meta Stake With $121M Bet, But CEO Morfit Supports Mark Zuckerberg's AI Vision: Here's What Investors Should Know

Morgan Stanley analyst Chris Quintero maintains BlackLine (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BL#NASDAQ">BL</a>) with a Overweight and raises the price target from $70 to $80.

Morgan Stanley Maintains Overweight on BlackLine, Raises Price Target to $80

Morgan Stanley analyst Elizabeth Porter maintains Zeta Global Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ZETA#NYSE">ZETA</a>) with a Equal-Weight and lowers the price target from $41 to $26.

ZETA

Morgan Stanley Maintains Equal-Weight on Zeta Global Holdings, Lowers Price Target to $26

HC Wainwright &amp; Co. analyst Swayampakula Ramakanth reiterates Innate Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IPHA#NASDAQ">IPHA</a>) with a Buy and maintains $11.5 price target.

IPHA

HC Wainwright & Co. Reiterates Buy on Innate Pharma, Maintains $11.5 Price Target

Morgan Stanley analyst Michael Phillips maintains Lemonade (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LMND#NYSE">LMND</a>) with a Underweight and raises the price target from $15 to $23.

LMND

Morgan Stanley Maintains Underweight on Lemonade, Raises Price Target to $23

TZUP

Thumzup shares are trading higher after the company announced its board of directors approved Bitcoin as a treasury reserve asset.

EYEN

Eyenovia shares are trading lower after the company announced that its CHAPERONE trial is not meeting its primary endpoint, prompting the discontinuation of the study and a review of the full data set to evaluate next steps for the program.

Morgan Stanley analyst Joseph Moore maintains Applied Mat (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMAT#NASDAQ">AMAT</a>) with a Equal-Weight and lowers the price target from $185 to $179.

Morgan Stanley Maintains Equal-Weight on Applied Mat, Lowers Price Target to $179

HC Wainwright &amp; Co. analyst Swayampakula Ramakanth reiterates ITeos Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ITOS#NASDAQ">ITOS</a>) with a Buy and maintains $46 price target.

ITOS

HC Wainwright & Co. Reiterates Buy on ITeos Therapeutics, Maintains $46 Price Target

NEWP

New Pacific Metals Announces Filing Of Preliminary Economic Assessment For The Carangas Project

The Arena Group Holdings, Inc. (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/AREN#AMEX">AREN</a>) shares jumped premarket on Friday after the company delivered the first quarter of<a href="https://www.benzinga.com/pressreleases/24/11/b41989682/the-arena-group-generates-4-0-million-in-net-income-for-third-quarter-of-2024-first-ever-profitabl" target="_blank" rel="noreferrer noopener"> positive net income</a>.
Arena, which is home to hundreds of media brands, including TheStreet, Parade Media, Men&#8217;s Journal, Surfer, Powder and Athlon Sports, reported a net income of $4.0 million, or EPS of $0.11, in the third quarter of 2024, compared to a net loss of $11.2 million, or EPS loss of $0.47 per share a year ago quarter.
Adjusted EBITDA stood at $11.2 million compared to $3.1 million a year ago quarter. Revenue from continuing operations came in at $33.6 million, vs. $37.0 million a year ago quarter.
The company reduced quarterly operating expenses by 51% year-over-year, achieving a $13.6 million positive swing in quarterly income from continuing operations. This highlights the rapid effectiveness of its transformation plan.
The Arena Group CEO Sara Silverstein said, &#8220;We&#8217;re achieving meaningful revenue diversification, including a significant increase in e-commerce and other revenue, enabling a substantial improvement in profitability. We generated higher gross margins, returned to positive operating income, and delivered our first-ever quarter of positive net income.&#8221;
Arena&#8217;s affiliate commerce business grew 287% during the six months, driven by strong organic traffic to commerce posts and stronger partnerships with retailers who value its highly transactional audience.
The company expanded its commerce coverage while increasing revenue per post by 57% in the third quarter versus second quarter of 2024.
Arena finalized a deal to license its proprietary content management system, which also included the acquisition of multiple sites, notably the top-tier automotive platform Autoblog.
Additionally, Arena extended the maturity of its credit line with Simplify Inventions, LLC, and converted $15 million of debt into common equity.
Price Action: AREN shares are up 210% at $1.76 premarket at the last check Friday.
Photo via 761409 from Pixabay
Read Next:
<ul>
<li><a href="https://www.benzinga.com//node/42002487" target="_blank" rel="noreferrer noopener">Mounjaro-Maker Eli Lilly Files Lawsuit Against US Agency Over Drug Rebate Program</a></li>
</ul>

Earnings

Small Cap

AREN

Why Is TheStreet Parent Arena Group Stock Rocketing Premarket Friday?

Thumzup Board Approves Purchase Of Up To $1M In Bitcoin

Tech stocks that are down more than 20% over the past 3 months

J.P. Morgan analyst Reginald Smith maintained a Buy rating on Kaspi.kz JSC Sponsored ADR RegS (KSPI – Research Report) today and set a price target...

Kaspi.kz JSC Sponsored ADR RegS (KSPI) Receives a Buy from J.P. Morgan

Kaspi.kz JSC Sponsored ADR RegS (KSPI) has released an update. Kaspi.kz JSC has entered into a stock purchase agreement to acquire shares from Turk...

Kaspi.kz Acquires Shares to Boost Market Presence

Kaspi.kz JSC Sponsored ADR RegS (KSPI) has released an update. Kaspi.kz has reported strong financial performance for the first nine months of 2024...

Kaspi.kz Reports Robust Growth and Strategic Expansion

Kaspi.kz JSC Sponsored ADR RegS (KSPI) has released an update. Kaspi.kz JSC has announced an Extraordinary General Meeting on November 19, 2024, wh...

Kaspi.kz Announces Key Shareholder Meeting and Dividend Plans

Joint Stock Company Kaspi.kz (KSPI) Q3 2024 Earnings Call Transcript

Joint Stock Company Kaspi.kz reports Q3 results

Hepsiburada Changes Everything For Kaspi

Kaspi.kz JSC Sponsored ADR RegS (KSPI) has released an update. Kaspi.kz JSC has demonstrated robust financial performance for the nine months endin...

Kaspi.kz Reports Strong Revenue and Income Growth

Citi analyst Ygal Arounian initiated coverage of Kaspi.kz (KSPI) with a Buy rating and $140 price target The firm sees a continued "strong growth r...

Kaspi.kz initiated with a Buy at Citi

ASML

CRWD

HEPS

INTC

LRCX

OKTA

SMCI

SNOW

Press Releases

Rosen Law Firm Encourages Joint Stock Company Kaspi.kz Investors to Inquire About Securities Class Action Investigation - KSPI

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Joint Stock Company Kaspi.kz - KSPI

KSPI INVESTOR NEWS: Joint Stock Company Kaspi.kz Investors that Suffered Losses are Encouraged to Contact Rosen Law about Ongoing Investigation into Company – KSPI

Legal

Kaspi.kz Investors: Company Investigated by the Portnoy Law Firm

Wolf Haldenstein Adler Freeman & Herz LLP announces that it is investigating Joint Stock Company Kaspi.kz AO for potential violations of federal securities laws

KSPI BREAKING NEWS: Joint Stock Company Kaspi.kz Investors that Suffered Losses are Encouraged to Contact Rosen Law about Ongoing Investigation into Company – KSPI

Joint Stock Company Kaspi.kz Announcement: If You Have Suffered Losses in Joint Stock Company Kaspi.kz (NASDAQ: KSPI), You Are Encouraged to Contact The Rosen Law Firm About Your Rights

KASPI ALERT: Bragar Eagel & Squire, P.C. is Investigating Joint Stock Company Kaspi.kz on Behalf of Kaspi Stockholders and Encourages Investors to Contact the Firm

Ally Financial

American Express

Bread Financial Holdings, Inc. Common Stock

Bread Finl Hldgs

Credit Acceptance Corporation - Common Stock

Credit Acceptance

Capital One Financial Corporation Common Stock

Capital One Finl

Dave

Discover Finl

Encore Capital Gr

Enova International

FirstCash Hldgs

FinVolution Group American Depositary Shares

FinVolution Gr

LendingClub

Lufax Holding Ltd American Depositary Shares, each representing two (2) Ordinary Shares

Lufax Holding

MoneyLion

Navient

Nelnet

Nerdwallet

OneMain Holdings

PRA Group

PROG Holdings

Qifu Technology, Inc - American Depositary Shares

Qifu Technology

SoFi Techs

Synchrony Finl

Upstart Hldgs

Citigroup

JP Morgan

New Street Research

Susquehanna

Wolfe Research

이들 10개 대형주는 지난주 최악의 성과를 거두었다. 그것들이 당신의 포트폴리오에 있나요?
1. 서밋 테라퓨틱스(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SMMT#NASDAQ">SMMT</a>)의 주식이 23.61% 하락했다. 이 회사는 새롭고 잠재적인 최초의 연구용 이중특이성 항체인 아이보네스시맙(ivonescimab)에 대한 데이터가 <a href="https://www.benzinga.com//node/40873837" target="_blank" rel="noreferrer noopener">2024년 ESMO 연례 회의</a>에서 발표되었다고 발표했다.
2. Joint Stock Company Kaspi.kz(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KSPI#NASDAQ">KSPI</a>)의 주식이 21.66% 급락했다. 이는 컬퍼 리서치(Culper Research)가 <a href="https://www.benzinga.com//node/40943334" target="_blank" rel="noreferrer noopener" data-google-interstitial="false">이 회사에 대한 공매도 보고서를 발표</a>한 후 주가는 21.66% 하락했다.
3. 바이오마린 파마슈티컬(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BMRN#NASDAQ">BMRN</a>)의 주식이 16.74% 하락했다. 이는 경쟁사인 아센디스 파마(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ASND#NASDAQ">ASND</a>)의 <a href="https://www.benzinga.com//node/40885653" target="_blank" rel="noreferrer noopener" data-google-interstitial="false">강력한 왜소증 치료제 데이터</a> 발표 이후 발생한 일이다.
4. 리비안 오토모티브(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RIVN#NASDAQ">RIVN</a>)의 주식이 <a href="https://www.benzinga.com//node/40961732" target="_blank" rel="noreferrer noopener">지난주</a> 13.26% 하락했다.
5. 페덱스(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FDX#NYSE">FDX</a>)의 주식은 회사가 예상보다 나쁜 1분기 재무 결과를 보고하고 <a href="https://www.benzinga.com//node/40948046" target="_blank" rel="noreferrer noopener">2025 회계연도 가이던스를 하향 조정</a>한 후 11.08% 하락했다.
6. 바이오엔텍 SE (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BNTX#NASDAQ">BNTX</a>)의 주식이 9.01% 하락했다. 화이자(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PFE#NYSE">PFE</a>)와 바이오엔텍은 유럽 연합에서 오미크론(omicron) KP.2 적응 <a href="https://www.benzinga.com//node/40956192" target="_blank" rel="noreferrer noopener" data-google-interstitial="false">코로나19 백신</a>에 대해 긍정적인 CHMP 의견을 받았다.
7. 아서 J 갤러거(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AJG#NYSE">AJG</a>)의 주식이 7.17% 하락했다. 여러 애널리스트들이 <a href="https://www.benzinga.com/quote/ajg/analyst-ratings" target="_blank" rel="noreferrer noopener">주가 목표를 상향 조정</a>한 후 발생한 일이다.
8. 츄이(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CHWY#NYSE">CHWY</a>)의 주식이 6.97% 하락했다. 이는 회사가 주식 공모와 <a href="https://www.benzinga.com//node/40949015" target="_blank" rel="noreferrer noopener">동시 주식 매입</a>을 발표한 후 발생한 일이다.
9. 노보 노디스크 A/S (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVO#NYSE">NVO</a>)의 주식은 비만 환자를 대상으로 한 몬루나반트(monlunabant)의 <a href="https://www.benzinga.com//node/40961934" target="_blank" rel="noreferrer noopener" data-google-interstitial="false">중간 단계 연구 결과가 헤드라인</a>을 장식한 후 6.93% 하락했다.
10. 머피 USA(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MUSA#NYSE">MUSA</a>)의 주식이 6.90% 하락했다. 이는 JP 모건이 주식 등급을 중립에서 비중축소(Underweight)로 하향 조정했지만 <a href="https://www.benzinga.com/quote/musa/analyst-ratings" target="_blank" rel="noreferrer noopener">목표 주가를 $415에서 $435로 상향 조정</a>한 후 발생한 일이다.
추가 읽기:
<ul>
<li><a href="https://kr.benzinga.com/news/usa/stocks/%EC%BD%98%EC%8A%A4%ED%85%94%EB%A0%88%EC%9D%B4%EC%85%98-%EB%B0%8F-%EC%B9%B4%EB%B0%94%EB%82%98%EB%8A%94-%EC%A7%80%EB%82%9C%EC%A3%BC-%EC%B5%9C%EA%B3%A0-%EC%84%B1%EA%B3%BC%EB%A5%BC-%EB%B3%B4%EC%97%AC/" target="_blank" rel="noopener">콘스텔레이션 및 카바나는 지난주 최고 성과를 보여준 11개 대형주 중 일부 (9월 16일-9월 20일)</a></li>
</ul>
사진 출처: Shutterstock
다른 트레이더들보다 30분 일찍 독점 시장 움직임 뉴스를 받아보세요 
Benzinga Pro의 14일 무료 체험을 통해 독점 뉴스 기사를 이용할 수 있어 수백만 명의 다른 트레이더보다 먼저 실행 가능한 거래 뉴스를 얻을 수 있습니다. <a href="https://www.benzinga.com/pro/register?t=be2bewe5mibe3bz3&amp;utm_source=bz-kor" target="_blank" rel="noreferrer noopener">여기를 클릭</a>하여 14일 무료 체험을 시작하세요.

Comments

Kaspi.kz

뉴스

에 대한 최신 뉴스 Kaspi.kz (NASDAQ:KSPI) 주식

월요일, 9월 23, 2024

사람들이 또한 지켜본다

뉴스

파트너 / 기고자

벤징가 글로벌